Nasal microbes in allergic rhinitis children with or without sublingual immunotherapy.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
27 Oct 2023
Historique:
medline: 1 11 2023
pubmed: 31 10 2023
entrez: 31 10 2023
Statut: ppublish

Résumé

The mechanism of allergic rhinitis (AR) remains unclear. Most researchers believe that AR is the result of a combination of environmental and genetic factors. Sublingual immunotherapy (SLIT) is a treatment that can change the natural course of AR through immunomodulatory mechanism and maintain efficacy after the treatment. Nasal cavity is the main site where AR patients contact with external allergens, produce inflammatory reactions and nasal symptoms. Therefore, in this study, we investigate the nasal microbiome in AR patients, and the changes after SLIT. In this cross-sectional study, nasal swabs for microbiome analysis were collected from 3 groups: SLIT-naïve AR patients (AR group), AR patients undergoing SLIT treatment over 2 years (SLIT group) and a control group (CG). The characteristics of nasal microbiome of each groups were produced by 16s-rDNA sequencing technology. The Simpson index of AR group was significantly higher than that of CG and SLIT groups, but not different between SLIT group and CG group. The abundance of Bacteroidete and Firmicutes remarkably increased in the AR group, but Bacteroidete reduced to CG level after SLIT. AR patients have different nasal microbiome composition, but we do not know how it happened and whether the AR condition affected nasal microbiome composition or nasal microbiome affected AR.

Identifiants

pubmed: 37904472
doi: 10.1097/MD.0000000000035711
pii: 00005792-202310270-00128
pmc: PMC10615503
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e35711

Informations de copyright

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors have no funding and conflicts of interest to disclose.

Références

Microbiome. 2014 Aug 11;2:27
pubmed: 25143824
J Allergy Clin Immunol. 2013 May;131(5):1288-96.e3
pubmed: 23498595
ISME J. 2016 Mar;10(3):533-45
pubmed: 26296065
Allergy Asthma Proc. 2012 Sep-Oct;33 Suppl 1:S113-41
pubmed: 22981425
Health Technol Assess. 2013 Jul;17(27):vi, xi-xiv, 1-322
pubmed: 23827204
PLoS One. 2013 Dec 30;8(12):e85507
pubmed: 24386477
Allergy Asthma Immunol Res. 2019 Mar;11(2):156-169
pubmed: 30661309
Clin Transl Allergy. 2015 May 22;5:12
pubmed: 26097680
Am J Rhinol Allergy. 2014 Jul-Aug;28(4):281-6
pubmed: 25197913
BMJ Open. 2019 Feb 19;9(2):e026518
pubmed: 30782945
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Apr 7;57(4):392-404
pubmed: 35359078
Expert Opin Biol Ther. 2018 Feb;18(2):197-204
pubmed: 29113525
Laryngoscope. 2020 Dec;130(12):E882-E888
pubmed: 32181890
Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43
pubmed: 25644617
BMJ Open Respir Res. 2018 Sep 23;5(1):e000324
pubmed: 30271607
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
JAMA Netw Open. 2020 Sep 1;3(9):e2015643
pubmed: 32876683
BMC Pulm Med. 2014 Jul 03;14:109
pubmed: 24990471
Inflamm Bowel Dis. 2016 May;22(5):1137-50
pubmed: 27070911
Int Arch Allergy Immunol. 2020;181(12):934-940
pubmed: 32937623
Allergy Rhinol (Providence). 2020 Mar 13;11:2152656720911605
pubmed: 32206384

Auteurs

Xiao-Fei Shen (XF)

Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Zhi-Pan Teng (ZP)

Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Qi Li (Q)

Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Zhen-Kun Yu (ZK)

Department of Otorhinolaryngology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH